From FDA labels and ClinicalTrials.gov

Do GLP-1s help fatty liver disease?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

FDA has approved Wegovy for this, in the words of each label below. ESSENCE (Semaglutide): A planned interim result at 72 weeks from the first 800 of 1,197 people, in a trial still running. Steatohepatitis resolved without worse fibrosis in 62.9% on semaglutide against 34.3% on placebo. Fibrosis improved without worse steatohepatitis in 36.8% against 22.4%. N Engl J Med, 2025 (pubmed.ncbi.nlm.nih.gov/40305708). ClinicalTrials.gov lists 73 trials of these medicines on it: 13 with posted results and 10 recruiting now.

Read from the registry and PubMed every day. The newest update here is Nov 18, 2026.

FDA approved

What each label says on fatty liver disease

The approved use, word for word from each current label.

  • Wegovy: for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial.
Published results

What the largest trials on fatty liver disease found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

ESSENCE

Semaglutide · 800 people · Better than the comparison · Placebo-controlled randomized trial

A planned interim result at 72 weeks from the first 800 of 1,197 people, in a trial still running. Steatohepatitis resolved without worse fibrosis in 62.9% on semaglutide against 34.3% on placebo. Fibrosis improved without worse steatohepatitis in 36.8% against 22.4%.

N Engl J Med, 2025 (pubmed.ncbi.nlm.nih.gov/40305708)

SYNERGY-NASH

Tirzepatide · 190 people · Better than the comparison · Placebo-controlled randomized trial

A Phase 2 trial. MASH resolved without worse fibrosis in 62% on 15 mg against 10% on placebo. Fibrosis improved by a stage in 51% against 30%.

N Engl J Med, 2024 (pubmed.ncbi.nlm.nih.gov/38856224)

The registry

Trials on fatty liver disease, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Semaglutide3374
Liraglutide1100
Exenatide640
Pemvidutide601
Survodutide512
Dulaglutide400
Tirzepatide412
Mazdutide301
VK2735100
Posted results

What trials on fatty liver disease reported

Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.

TrialMedicinePhasePeopleResult
APPLELiver and Fat Regulation in Overweight Adolescent GirlsExenatidePhase 2/392Hepatic Glucose Release (mg/kg/min), Measured up to 4 months from enrollment. Control: 1.85; PCOS Medication Naive: 1.46; PCOS, Medication Naive + Byetta: 1.54; PCOS on COCPs: 1.88; PCOS on Metformin: 1.57.
TEALTreating PCOS With Semaglutide vs Active Lifestyle InterventionSemaglutidePhase 2/360Change in Hepatic Fat Fraction (Change in percentage of liver fat), Baseline and 12 weeks. Diet Intervention: -1.41; GLP-1 Intervention: -1.84.
NAFLDRole of Exenatide in NASH-a Pilot StudyExenatidePhase 2/38On ClinicalTrials.gov (clinicaltrials.gov)
NCT01006889Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver DiseaseExenatidePhase 424On ClinicalTrials.gov (clinicaltrials.gov)
WAYFINDStudy of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)SemaglutidePhase 2457Percentage of Participants Who Achieved ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 72 in Semaglutide (SEMA) + Cilofexor/Firsocostat (CILO/FIR) Fixed Dose Combination (FDC) Versus Placebo Groups (percentage of participants), Week 72. SEMA + CILO/FIR FDC: 13.7; PTM SEMA + PTM CILO/FIR: 8.3.
NCT02970942Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.SemaglutidePhase 2320Percentage of Participants With Non- Alcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 72 Weeks (Yes/No) (Percentage of participants), After 72 weeks, Yes. Semaglutide 0.1 mg: 40.4; Semaglutide 0.2 mg: 35.6; Semaglutide 0.4 mg: 58.9; Placebo: 17.2.
NCT04771273A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)SurvodutidePhase 2295Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment (Percentage of participants), At baseline and at 48 weeks.. Survodutide 2.4 mg - Actual Maintenance Treatment: 38.7; Survodutide 4.8 mg - Actual Maintenance Treatment: 63.8; Survodutide 6.0 mg - Actual Maintenance Treatment: 55.8; Placebo - Actual Maintenance Treatment: 15.2.
SYNERGY-NASHA Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)TirzepatidePhase 2190Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology (Percentage of participants), Week 52. 5 mg Tirzepatide: 51.84; 10 mg Tirzepatide: 63.13; 15 mg Tirzepatide: 73.92; Placebo: 12.62.
NCT04944992A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)SemaglutidePhase 2145Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 Weeks (Percent Reduction), Baseline and up to ~24 Weeks. Efinopegdutide: 72.7; Semaglutide: 42.3.
NCT03987074Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)SemaglutidePhase 2109Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) (percentage of participants), First dose date up to Week 24 plus 30 days. Semaglutide: 81.0; Semaglutide + Firsocostat 20 mg: 86.4; Semaglutide + Cilofexor 30 mg: 81.8; Semaglutide + Cilofexor 100 mg: 72.7; Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg: 90.5.
NCT03987451A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver DamageSemaglutidePhase 271Percentage of Participants With At Least One Stage of Liver Fibrosis Improvement With No Worsening of Non-Alcoholic Steatohepatitis (NASH) After 48 Weeks (Percentage of participants), Week 48. Semaglutide 2.4 mg: 10.6; Placebo: 29.2.
NCT04216589Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)SemaglutidePhase 251On ClinicalTrials.gov (clinicaltrials.gov)
NCT00529204Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver DiseaseExenatidePhase 21On ClinicalTrials.gov (clinicaltrials.gov)
Recruiting now

Trials on fatty liver disease taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis (clinicaltrials.gov/study/NCT06632444)SurvodutidePhase 3Dec 27, 2031
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH (clinicaltrials.gov/study/NCT07795164)PemvidutidePhase 3Dec 2032
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis (clinicaltrials.gov/study/NCT06632457)SurvodutidePhase 3Jun 5, 2029
Fibrosis Lessens After Metabolic Surgery (clinicaltrials.gov/study/NCT06374875)SemaglutidePhase 4Dec 31, 2029
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) (clinicaltrials.gov/study/NCT07718126)MazdutidePhase 4Aug 31, 2029
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD (clinicaltrials.gov/study/NCT07527910)TirzepatidePhase 2Mar 15, 2030
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) (clinicaltrials.gov/study/NCT03884075)SemaglutidePhase 2Oct 2, 2028
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant (clinicaltrials.gov/study/NCT05424003)SemaglutidePhase 2Aug 1, 2026
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (clinicaltrials.gov/study/NCT07391267)SemaglutideNot phasedDec 31, 2028
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity (clinicaltrials.gov/study/NCT06934642)TirzepatidePhase 1Oct 2026
From PubMed

Newest papers on GLP-1s and fatty liver disease

  • GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis (pubmed.ncbi.nlm.nih.gov/43002386)

    Meta-analysis · Dig Dis · Nov 9, 2026 · Polepalli KV et al.

  • Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): A systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/42937793)

    Meta-analysis · Medicine (Baltimore) · Oct 1, 2026 · Alfawaz M et al.

  • Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial (pubmed.ncbi.nlm.nih.gov/42605535)

    Randomized trial · Diabetes Obes Metab · Aug 17, 2026 · Miyake T et al. · cited by 1

  • EQ-5D health utility gains with once-weekly semaglutide 2.4 mg in people with MASH and F2/F3 fibrosis: An analysis of ESSENCE (pubmed.ncbi.nlm.nih.gov/42580587)

    Randomized trial · JHEP Rep · Aug 11, 2026 · Augusto M et al. · cited by 1

  • GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of randomized controlled trials (pubmed.ncbi.nlm.nih.gov/42509395)

    Meta-analysis · Hepatol Int · Jul 27, 2026 · Sun SP et al.

  • The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial (pubmed.ncbi.nlm.nih.gov/42480572)

    Randomized trial · Lancet Gastroenterol Hepatol · Jul 21, 2026 · Noureddin M et al.

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Updated automatically

What changed in trials on fatty liver disease

  • TrialSemaglutide study now recruiting (was not yet recruiting): Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (clinicaltrials.gov/study/NCT07391267)
  • TrialSemaglutide study now active, not recruiting (was not yet recruiting): A Retrospective Real-World Cohort Study (clinicaltrials.gov/study/NCT07781371)
  • TrialNew Survodutide study registered: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease (clinicaltrials.gov/study/NCT07850063)

Written from each source's own record as it changes. Every change on GLPcompare

Questions

GLP-1s and fatty liver disease: common questions

What did the largest trial on fatty liver disease find?

ESSENCE (Semaglutide, 800 people): A planned interim result at 72 weeks from the first 800 of 1,197 people, in a trial still running. Steatohepatitis resolved without worse fibrosis in 62.9% on semaglutide against 34.3% on placebo. Fibrosis improved without worse steatohepatitis in 36.8% against 22.4%.

Is any GLP-1 FDA approved for fatty liver disease?

Yes: Wegovy. Wegovy's label: for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial.

Does insurance cover a GLP-1 for fatty liver disease?

Plans decide, and they usually tie coverage to a medicine's approved uses, so Wegovy is the place to start. Ask your plan whether it covers the medicine for this diagnosis and whether it needs prior authorization.

Which GLP-1 has been studied most for fatty liver disease?

Semaglutide, with 33 registered trials on it, then Liraglutide with 11. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for fatty liver disease?

10 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.